Incyte Corporation vs Western Alliance Bancorporation — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Western Alliance Bancorporation trades at $79.8 (market cap $8.84B). The key difference: Incyte Corporation is far larger — about 2.6× Western Alliance Bancorporation's market cap, and Western Alliance Bancorporation pays a 2.07% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | WAL | |
|---|---|---|
Market Cap | $23.11B | $8.84B |
Sector | Health | Financials |
52-Week High | $118.52 | $96.08 |
52-Week Low | $67.38 | $66.70 |
Enterprise Value | $19.13B | — |
Dividend Yield | — | 2.07% |
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →